Amgen Inc. (NASDAQ:AMGN) Stock Holdings Reduced by Cognios Beta Neutral Large Cap Fund LP

Cognios Beta Neutral Large Cap Fund LP lowered its position in Amgen Inc. (NASDAQ:AMGN) by 8.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,135 shares of the medical research company’s stock after selling 202 shares during the quarter. Cognios Beta Neutral Large Cap Fund LP’s holdings in Amgen were worth $615,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Briaud Financial Planning Inc purchased a new position in Amgen in the third quarter valued at about $26,000. BOK Financial Private Wealth Inc. purchased a new position in Amgen in the fourth quarter valued at about $29,000. OFI Invest Asset Management bought a new stake in shares of Amgen during the 3rd quarter worth about $26,000. Planned Solutions Inc. bought a new stake in shares of Amgen during the 4th quarter worth about $30,000. Finally, Providence Capital Advisors LLC bought a new stake in shares of Amgen during the 3rd quarter worth about $30,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

AMGN has been the subject of several recent analyst reports. Leerink Partnrs downgraded Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 7th. StockNews.com downgraded Amgen from a “buy” rating to a “hold” rating in a research note on Thursday, March 28th. Oppenheimer reiterated an “outperform” rating and set a $350.00 price target on shares of Amgen in a research note on Thursday, February 1st. TD Cowen decreased their target price on Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a research note on Wednesday, April 17th. Finally, Truist Financial restated a “buy” rating and set a $320.00 target price on shares of Amgen in a research note on Friday, April 12th. Ten analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $296.95.

Amgen Price Performance

Shares of AMGN traded down $0.53 during mid-day trading on Wednesday, reaching $273.01. The company had a trading volume of 2,466,582 shares, compared to its average volume of 2,840,533. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $329.72. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The company’s 50-day moving average is $276.11 and its 200-day moving average is $281.61. The company has a market capitalization of $146.44 billion, a P/E ratio of 21.72, a P/E/G ratio of 2.53 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The business had revenue of $8.20 billion during the quarter, compared to analysts’ expectations of $8.13 billion. During the same period in the prior year, the firm posted $4.09 EPS. Amgen’s quarterly revenue was up 19.8% compared to the same quarter last year. On average, equities analysts anticipate that Amgen Inc. will post 19.45 EPS for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be given a dividend of $2.25 per share. The ex-dividend date is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a yield of 3.30%. Amgen’s dividend payout ratio (DPR) is presently 72.06%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.